Data gathered: November 27
Alternative Data for Lipocine
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 2,000 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 2 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 14,705 | Sign up | Sign up | Sign up |
| Twitter Mentions | 27 | Sign up | Sign up | Sign up |
| News Mentions | 1 | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
About Lipocine
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceuticals for the treatment of metabolic and endocrine disorders. The company is headquartered in Salt Lake City, Utah.
| Price | $4.45 |
| Target Price | Sign up |
| Volume | 41,470 |
| Market Cap | $27M |
| Year Range | $3.52 - $10.69 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
Lipocine (NASDAQ:LPCN) Now Covered by Analysts at StockNews.comNovember 25 - ETF Daily News |
 |
Lipocine Announces Publication and Discussion of LPCN 1148 Manuscript at The Liver Meeting 2024 Editor's Cut SessionNovember 17 - Yahoo |
|
Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2024November 6 - Yahoo |
 |
Lipocine: Q3 Earnings SnapshotNovember 6 - Yahoo |
 |
Lipocine (NASDAQ:LPCN) Presents Positive Data on LPCN 2401 at Obesity Society ConferenceNovember 5 - ETF Daily News |
|
Lipocine Announces Distribution and License Agreement with SPC Korea to Commercialize TLANDO® in South KoreaOctober 30 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 0 | 1M | -1M | -2.2M | -2.6M | -0.410 |
| Q2 '24 | 90,000 | 1.5M | -1.4M | -3.1M | -3.3M | -0.570 |
| Q1 '24 | 7.6M | 1.6M | 6M | 3.5M | 3.2M | 0.660 |
| Q4 '23 | 220,000 | 1.1M | -930,000 | -2.3M | -2.6M | -0.420 |
| Q3 '23 | -3.1M | 1M | -4.2M | -6.7M | -7M | -1.270 |
Insider Transactions View All
| Patel Mahesh V. filed to buy 107,418 shares at $5. May 25 '23 |
| Patel Mahesh V. filed to buy 1,678,090 shares at $0.3. March 24 '23 |
| Ono Richard Dana filed to buy 14,125 shares at $0.3. March 20 '23 |
| Patel Mahesh V. filed to buy 1,528,090 shares at $0.3. March 17 '23 |
| Papapetropoulos Spyros filed to buy 21,739 shares at $0.5. November 28 '22 |
Similar companies
Read more about Lipocine (LPCN) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter mentions, news mentions & customer reviews.
What is the Market Cap of Lipocine?
The Market Cap of Lipocine is $27M.
What is the current stock price of Lipocine?
Currently, the price of one share of Lipocine stock is $4.45.
How can I analyze the LPCN stock price chart for investment decisions?
The LPCN stock price chart above provides a comprehensive visual representation of Lipocine's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Lipocine shares. Our platform offers an up-to-date LPCN stock price chart, along with technical data analysis and alternative data insights.
Does LPCN offer dividends to its shareholders?
As of our latest update, Lipocine (LPCN) does not offer dividends to its shareholders. Investors interested in Lipocine should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Lipocine?
Some of the similar stocks of Lipocine are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.